Companies / Philippines
Blow For Research-Based Drugmakers
February 2007 | Legal NewsThe Philippines has made it easier for generic drugs to enter the marketplace thereby reducing the amount of time a branded drug has exclusivity, much to the annoyance of research-based pharmaceutical companies. While the development will negatively impact the multinationals in the short-term, BMI believes that the improved intellectual property environment will protect the long-standing interests of foreign firms.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
